2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …

Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Type 2 diabetes accounts for nearly 90% of the approximately 537 million cases of diabetes
worldwide. The number affected is increasing rapidly with alarming trends in children and …

Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

Objective To develop new antiphospholipid syndrome (APS) classification criteria with high
specificity for use in observational studies and trials, jointly supported by the American …

Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

Cardiovascular disease remains the leading cause of death in patients with diabetes.
Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk …

Obesity is now recognised as a disease that is associated with serious morbidity and
increased mortality. One of its main metabolic complications is type 2 diabetes, as the two …